{
  "kind": "framework",
  "value": "consort-flow-diagram",
  "collectionKey": "slides:framework:consort-flow-diagram:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 9,
  "page": 1,
  "pageSize": 24,
  "pageCount": 1,
  "rows": [
    {
      "docId": "019de074-1527-7308-955d-4c9eab2bbacb",
      "docSlug": "e812f3c221148b99b15c4527dea8f94b",
      "documentTitle": "argenx SE | Results Presentation Deck | 15 slides",
      "authorId": "argenx-se",
      "authorName": "argenx",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "appendix_methodology",
      "function": "illustrate_case",
      "notes": "Standard clinical trial participant flow diagram.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standard clinical trial participant disposition flow chart",
      "slideHref": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/5",
      "deckHref": "/decks/019de074-1527-7308-955d-4c9eab2bbacb",
      "deckAnchorHref": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-5",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de071-753f-7227-aa1d-36a319c59353",
      "docSlug": "7013d0966bfedd0d757b9fa24a480455",
      "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 34 slides",
      "authorId": "astrazeneca",
      "authorName": "AstraZeneca",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2021-09-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "appendix_methodology",
      "function": "analyze_data",
      "notes": "Standard clinical trial patient flow diagram.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standard clinical trial reporting structure",
      "slideHref": "/slides/019de071-753f-7227-aa1d-36a319c59353/10",
      "deckHref": "/decks/019de071-753f-7227-aa1d-36a319c59353",
      "deckAnchorHref": "/decks/019de071-753f-7227-aa1d-36a319c59353#slide-10",
      "loopMatches": [
        {
          "to": 17,
          "from": 6,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "f6f774ca-af54-4b25-aa3a-3b940b789d31",
          "evidence": "The deck highlights the limitations of current treatments and Enhertu's potential to improve patient outcomes.",
          "position": 0,
          "objective": "What are the consequences of not adopting Enhertu as the standard of care?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        },
        {
          "to": 14,
          "from": 9,
          "name": "Hypothesis Test",
          "slug": "42-hypothesis-test",
          "bestFor": "Strategy validation, due diligence, research presentations",
          "matchId": "4c136f41-d14c-4c9d-b4d4-01b2328be5bb",
          "evidence": "The deck presents detailed trial data to support Enhertu's efficacy and safety.",
          "position": 1,
          "objective": "How does Enhertu's data support its potential as a standard of care?",
          "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
          "confidence": 0.7,
          "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 14,
          "from": 9,
          "beatId": "7d6fc11c-9c63-4d02-bc07-8fe706170a68",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Product",
          "beatSlug": "sequoia-pitch-product",
          "evidence": "Detailed data on Enhertu's efficacy and safety",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de073-7e4e-7689-a01c-e0840dac2b61",
      "docSlug": "97e34d6c4db7d9454440fee3efd43545",
      "documentTitle": "Axcella Health | Results Presentation Deck | 62 slides",
      "authorId": "axcella-health",
      "authorName": "Axcella Therapeutics",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-09-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7761332,
      "pageNumber": 12,
      "slideType": "appendix_methodology",
      "function": "analyze_data",
      "notes": "Standard clinical trial subject disposition flow chart.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standard clinical trial subject disposition structure",
      "slideHref": "/slides/019de073-7e4e-7689-a01c-e0840dac2b61/12",
      "deckHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61",
      "deckAnchorHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61#slide-12",
      "loopMatches": [
        {
          "to": 36,
          "from": 6,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "de6af44a-f17d-4c55-adca-ab6e25c41e5d",
          "evidence": "The presentation highlights the need for effective treatment options and the risks associated with disease progression",
          "position": 0,
          "objective": "What is the risk of not treating NASH effectively?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-622c-750b-8b9a-648c05e927ed",
      "docSlug": "ea3395f0d3bd",
      "documentTitle": "Inspire Medical Systems, Inc. (INSP)",
      "authorId": "60_Wolfpack_Research",
      "authorName": "Wolfpack Research",
      "documentKindSlug": "research-note",
      "documentKindLabel": "Research note",
      "sourceTypeSlug": "short_seller",
      "sourceTypeLabel": "Short seller",
      "presentationDate": "2020-04-22 00:00:00",
      "orientation": "portrait",
      "aspectRatio": 0.77272725,
      "pageNumber": 53,
      "slideType": "appendix_methodology",
      "function": "appendix",
      "notes": "The slide uses a standard CONSORT-style flow diagram for clinical trial patient disposition.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standard clinical trial patient disposition flow",
      "slideHref": "/slides/019dd923-622c-750b-8b9a-648c05e927ed/53",
      "deckHref": "/decks/019dd923-622c-750b-8b9a-648c05e927ed",
      "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-648c05e927ed#slide-53",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 57,
          "from": 21,
          "beatId": "8d3b0744-2575-4484-a38c-fef195030616",
          "arcName": "Overcoming the Monster",
          "arcSlug": "overcoming-monster",
          "beatName": "The Victory",
          "beatSlug": "overcoming-monster-the-victory",
          "evidence": "The document presents evidence and data to support the critique",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de072-b09f-7797-83e5-c925df87e1b3",
      "docSlug": "fb96dc8e32131cd826524e728a742819",
      "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 36 slides",
      "authorId": "compass-therapeutics",
      "authorName": "Compass Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-05-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "appendix_methodology",
      "function": "cite_precedent",
      "notes": "The diagram illustrates the patient disposition in a clinical trial, a standard methodology for reporting clinical study results.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standard clinical trial patient disposition flowchart",
      "slideHref": "/slides/019de072-b09f-7797-83e5-c925df87e1b3/9",
      "deckHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3",
      "deckAnchorHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3#slide-9",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 6,
          "beatId": "4553c68f-c8a6-4cb5-9d28-9bc65dfd58fa",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Problem",
          "beatSlug": "problem-agitate-solution-problem-identify-pain",
          "evidence": "Slides 6-17 identify the problem, highlighting the unmet needs in BTC treatment.",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de072-b09f-7797-83e5-c925df87e1b3",
      "docSlug": "fb96dc8e32131cd826524e728a742819",
      "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 36 slides",
      "authorId": "compass-therapeutics",
      "authorName": "Compass Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-05-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "appendix_methodology",
      "function": "present_framework",
      "notes": "Standard clinical trial CONSORT flow diagram.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standardized clinical trial reporting structure",
      "slideHref": "/slides/019de072-b09f-7797-83e5-c925df87e1b3/21",
      "deckHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3",
      "deckAnchorHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3#slide-21",
      "loopMatches": [
        {
          "to": 24,
          "from": 16,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "05173e5b-462d-46a8-b79a-b596b9de2b77",
          "evidence": "Slides 16-24 highlight the limitations of current treatments, implying the cost of inaction.",
          "position": 0,
          "objective": "What is the cost of not addressing the unmet needs in BTC treatment?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 16,
          "beatId": "f6eca836-c306-461a-9e22-743547581023",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Agitate",
          "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
          "evidence": "Slides 16-24 agitate the problem, emphasizing the limitations of current treatments.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Development",
          "parentBeatSlug": "development"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
      "docSlug": "f3db2294dcf9",
      "documentTitle": "Harmony Biosciences (HRMY)",
      "authorId": "58_Scorpion_Capital",
      "authorName": "Scorpion Capital",
      "documentKindSlug": "research-note",
      "documentKindLabel": "Research note",
      "sourceTypeSlug": "short_seller",
      "sourceTypeLabel": "Short seller",
      "presentationDate": "2023-03-28 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.3333334,
      "pageNumber": 242,
      "slideType": "expose_contradiction",
      "function": "expose_contradiction",
      "notes": "The slide uses a CONSORT-style flow diagram to illustrate patient attrition in a clinical trial.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "The diagram follows the standard structure for reporting patient flow in clinical trials.",
      "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/242",
      "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
      "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-242",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de077-691b-72c2-80d2-a28de652ce70",
      "docSlug": "7b833127c4e1241e21c155446b1ba76b",
      "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
      "authorId": "mindmed",
      "authorName": "MindMed",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-12-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 31,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The slide uses a CONSORT-style flow diagram to track patient retention.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standard clinical trial participant disposition reporting structure",
      "slideHref": "/slides/019de077-691b-72c2-80d2-a28de652ce70/31",
      "deckHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70",
      "deckAnchorHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70#slide-31",
      "loopMatches": [
        {
          "to": 42,
          "from": 3,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "6a4562d9-e1ba-4048-9ae4-0523b32c6d36",
          "evidence": "The document follows the golden circle framework, starting with the company's vision (why) and presenting its approach (how) and solution (what).",
          "position": 1,
          "objective": "Presenting the company's vision and approach",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.6,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 16,
          "beatId": "c93e54c1-7fba-4f94-ae19-b53dc410f312",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "The traction section spans multiple pages, showcasing the results of clinical trials and the potential of MM120.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de073-9523-714b-a2b4-ffafcdbd0ef0",
      "docSlug": "bc9bef6f52d4d9603180b6eb6c4f9d10",
      "documentTitle": "SAB Biotherapeutics | Results Presentation Deck | 12 slides",
      "authorId": "sab-biotherapeutics",
      "authorName": "SAB Biotherapeutics",
      "documentKindSlug": "regulatory-filing",
      "documentKindLabel": "Regulatory filing",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-09-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "appendix_data",
      "function": "summarize",
      "notes": "Standard CONSORT-style participant flow diagram.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standard clinical trial participant disposition structure",
      "slideHref": "/slides/019de073-9523-714b-a2b4-ffafcdbd0ef0/8",
      "deckHref": "/decks/019de073-9523-714b-a2b4-ffafcdbd0ef0",
      "deckAnchorHref": "/decks/019de073-9523-714b-a2b4-ffafcdbd0ef0#slide-8",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}